Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intravenous use. It is employed to treat autoimmune disorders and certain cancers in adult and pediatric patients.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across autoimmune and oncologic disease families where folate pathway inhibition is required.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: eradicates rapidly dividing leukemic cells. - Non‑Hodgkin lymphoma: contributes to remission by inhibiting tumor cell replication. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Mucositis or oral ulceration - Fatigue or malaise - Alopecia (hair loss) - Elevated liver enzymes - Mild skin rash

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Pulmonary toxicity (interstitial pneumonitis) - Severe hepatotoxicity or fibrosis - Acute renal failure - Life‑threatening infection - Secondary malignancies (e.g., leukemia)

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Pregnancy: contraindicated (Category X); teratogenic risk is high. - Renal function: assess baseline and monitor regularly; dose adjust if impairment occurs. - Hepatic function: check liver enzymes before initiation and periodically thereafter. - Hematologic monitoring: perform complete blood counts to detect marrow suppression. - Infection risk: avoid live vaccines and monitor for signs of infection. - Elderly patients: consider dose reduction and close observation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: may raise serum levels. - Sulfonamide antibiotics: additive bone‑marrow suppression. - Live vaccines: heightened risk of severe infection. - Alcohol: exacerbates hepatotoxicity.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance. - Azathioprine or other immunosuppressants: additive myelosuppression. - Warfarin: potential for enhanced anticoagulant effect. - Phenytoin: may reduce methotrexate efficacy. - Trimethoprim‑sulfamethoxazole: increased risk of hematologic toxicity.